LSB Research Group LLC

1. Moderna TX, Inc. $20,455,415 1,302 payments
2. Pfizer Inc. $6,298,477 434 payments
3. Emergent BioSolutions Inc. $3,976,665 4,051 payments
4. Novavax Inc $1,755,379 183 payments
5. GlaxoSmithKline, LLC. $1,371,643 130 payments
6. Teva Pharmaceuticals USA, Inc. $664,380 74 payments
7. Sanofi Pasteur Inc. $614,365 33 payments
8. Janssen Research & Development, LLC $191,653 13 payments
9. Octapharma USA, Inc. $134,817 12 payments
10. AbbVie, Inc. $132,874 8 payments

1. A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older $7,505,813 758 payments
2. A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants $7,033,824 166 payments
3. VELOCITY: An Anthrax Vaccine Clinical Study $3,617,935 4,048 payments
4. A Phase 123 Placebocontrolled Randomized Observerblind Dosefinding Study to Evaluate the Safety Tolerability Immunogenicity and Efficacy of Sarscov2 Rna Vaccine Candidates Against Covid19 in Healthy Adults $2,921,547 171 payments
5. A Phase 3 Master Protocol to Evaluate Additional Doses of Bnt162b2 in Healthy Individuals Previously Vaccinated With Bnt162b2 $1,727,621 63 payments
6. A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose Confirmation Study to Evaluate the Safety, Tolerability, and Immunogenicity of Lyophilized Zika Vaccine mRNA-1893 in Adults Aged 18-65 Years and Living in Endemic and Non Endemic Flavivi $1,191,669 42 payments
7. A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age $1,167,860 26 payments
8. A PHASE 2a, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, DOSE-CONFIRMATION STUDY TO EVALUATE THE SAFETY, REACTOGENICITY, AND IMMUNOGENICITY OF MRNA-1273 SARS-COV-2 VACCINE IN ADULTS AGED 18 YEARS AND OLDER $1,149,355 45 payments
9. A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 $715,984 79 payments
10. A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients with Schizophrenia $664,380 74 payments

1. Professional salary support $91,603 18 payments
2. Other $11,862 7 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.